Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.01.182428v1?rss=1 Authors: Stojakovic, A., Trushin, S., Sheu, A., Khalili, L., Chang, S.-Y., Li, X., Christensen, T., Salisbury, J. L., Geroux, R. E., Gateno, B., Flannery, P. J., Dehankar, M., Funk, C. C., Wilkins, J., Stepanova, A., OHagan, T., Galkin, A., Nesbitt, J., Zhu, X., Tripathi, U., Macura, S., Tchkonia, T., Pirtskhalava, T., Kirkland, J. L., Kudgus, R. A., Schoon, R. A., Reid, J. M., Yamazaki, Y., Kanekiyo, T., Zhang, S., Nemutlu, E., Dzeja, P., Jaspersen, A., Kwon, C. Y. I., Lee, M. K., Trushina, E. Abstract: We demonstrate that mitochondrial respiratory chain complex I is an important small molecule druggable target in Alzheimers Disease (AD). Partial inhibition of complex I triggers the AMP-activated protein kinase-dependent signaling network leading to neuroprotection in symptomatic APP/PS1 mice, a translational model of AD. Treatment of APP/PS1 mice with complex I inhibitor after the onset of AD-like neuropathology improved energy homeostasis, synaptic activity, long-term potentiation, dendritic spine maturation, cognitive function and proteostasis, and reduced oxidative stress and inflammation in brain and periphery, ultimately blocking the ongoing neurodegeneration. Therapeutic efficacy in vivo was monitored using translational biomarkers FDG-PET, 31P NMR, and metabolomics. Cross-validation of the mouse and the human AMP-AD transcriptomic data demonstrated that pathways improved by the treatment in APP/PS1 mice, including the immune system response and neurotransmission, represent mechanisms essential for therapeutic efficacy in AD patients. Copy rights belong to original authors. Visit the link for more info